Jazz Pharmaceuticals, Inc.
Symbol: JAZZ (NASDAQ)
118.46
▲ (1.54%) 1.794
Company Description:
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Key Stats
- Today's Open: $117.15
- Today's High: $118.464
- Today's Low: $115.475
- Today's Volume: 490.61K
- Yesterday Close: $116.67
- Yesterday High: $116.98
- Yesterday Low: $115.12
- Yesterday Volume: 544.69K
- Last Min Volume: 0
- Last Min High: $118.464
- Last Min Low: $118.453
- Last Min VWAP: $0
Company Profile
- Name: Jazz Pharmaceuticals, Inc.
- Website: https://www.jazzpharmaceuticals.com
- Listed Date: 2007-06-01
- Location: DUBLIN,
- Market Status: Active
- CIK Number: 0001232524
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $7.14B
- Round Lot: 100
- Outstanding Shares: 60.66M
- Asset Type: CS
RECENT FILINGS FOR JAZZ
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-08 | 144 | View |
| 2025-08-08 | 144 | View |
| 2025-08-08 | 144 | View |
| 2025-08-08 | 144 | View |
| 2025-08-08 | 144 | View |
| 2025-08-08 | 144 | View |
| 2025-08-08 | 144 | View |
| 2025-08-08 | 144 | View |
Latest News on JAZZ